open access to scientific and medical research

Back to Journals » Patient Related Outcome Measures » Volume 8

Original Research

Noteworthy comment: This paper is noteworthy because it describes a new tool to assess patients’ perspectives on a serious, often distressing aspect of a chronic mental illness—ie, cognitive impairment associated with schizophrenia. As recommended by the FDA’s guidance on patient-reported outcome (PRO) measures, the multistage development process utilized by the investigators incorporated quantitative and qualitative data from patients and providers. Given the importance to patients of receiving understandable information about their conditions, this new PRO measure may prove valuable in building a therapeutic alliance with patients with schizophrenia. Furthermore, following psychometric validation in an ongoing clinical trial, the measure could define key patient-oriented endpoints for future trials.

Highly-accessed

Initial development of a patient-reported outcome measure of experience with cognitive impairment associated with schizophrenia

Total article views		HTML views	PDF downloads	Totals
10,088	Dovepress*	8,813+	1,208	10,021
	PubMed Central*	1,275	279	1,554
	Totals	10,088	1,487	11,575
*Since 8 June 2017

Total mentioned	Facebook	Delicious	Reddit	Twitter	Others
2	0	0	0	1	1

View citations on PubMed Central and Google Scholar